HFpEF Susceptibility in Women: The Role of Inflammation
HFpEF Susceptibility in Women: The Role of Inflammation
批准号:
10595021
负责人:
Emily Lau
金额:
$19.96万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-04-01 至 2027-05-31
关键词:
Advisory CommitteesAffectAgeAnti-Inflammatory AgentsBiometryCardiacCardiometabolic DiseaseCardiovascular DiseasesCardiovascular systemCareer MobilityClinicalCommunitiesComplexDataDevelopmentDiseaseDisease ProgressionEFRACEicosanoidsEndothelial CellsEndotheliumExerciseFemaleFutureGene Expression ProfilingGoalsHeart failureHeterogeneityHospitalsHumanImmune responseImpairmentIndividualInflammationInflammation MediatorsInflammatoryInflammatory ResponseInvestigationKnowledgeLightLipidsMass Spectrum AnalysisMediatorMentorshipMethodsMolecularMorbidity - disease rateNested Case-Control StudyObesityObservational StudyOutcomePathogenesisPathway interactionsPatientsPerimenopausePhenotypePhysiciansPhysiologicalPostmenopausePredispositionPremenopausePrevalencePreventionProgram DevelopmentPublic HealthResearchResearch PersonnelResearch ProposalsRiskRoleScientistSex DifferencesStressStructureSymptomsTechniquesTechnologyTherapeuticTimeUnited StatesValidationVenousWomanWomen&aposs HealthWorkbiological sexcardiometabolic riskcardiovascular healthcardiovascular risk factorcareercareer developmentclinical heterogeneitycohortcomorbiditydesigndisease heterogeneityeffective therapyendothelial dysfunctionexercise intolerancehemodynamicsimprovedinflammatory markerinsightlongitudinal, prospective studymenmetabolomicsmortalitynovelpatient oriented researchpreservationprospectiveresponsesexskillssystemic inflammatory responsetranscriptomicsvalsartan
中文摘要
项目总结/摘要
心力衰竭(HF)是一个重要的公共卫生问题,在美国影响超过600万人
一个人射血分数保留的HF(HFpEF)现在是HF的主要形式,
继续上升。HFpEF仍然是一个治疗挑战,因为我们对因果关系的了解有限,
影响因素、HFpEF亚表型的临床异质性和缺乏可用的治疗。
HFpEF在女性中的流行率远高于男性,部分原因是心脏结构的性别差异,
重塑、对生理应激的适应和合并症负担。新出现的数据支持了
HFpEF发病机制中的全身炎症和免疫反应的性别差异导致许多
假设炎症是女性对HFpEF易感性的重要驱动因素。更好的
了解这些性别差异可能会提供关键的见解疾病的发病机制,特别是在光
最近的证据突出了沙库比曲/缬沙坦优先用于女性的潜在治疗益处,
HFpEF。迄今为止,HFpEF中炎症的研究仅限于HFpEF的下游标志物。
炎症类二十烷酸是小的生物活性脂质,其调节系统性代谢的上游起始。
人类的炎症使用质谱的先进方法现在可以快速准确地
定量超过150种上游类二十烷酸介体。我们将利用这种最先进的技术
更详细地了解上游类花生酸途径中的生物性别差异
导致HFpEF风险和疾病进展。在目标1中,我们将研究关联中的性别差异
循环类花生酸与HFpEF的临床前因以及社区中的HFpEF事件。在
目的2,我们将评估类二十烷酸分析物与心脏和心外反应的相关性,
临床HFpEF男性和女性的运动。在目标3中,我们将进行一项前瞻性观察研究,
研究通过类花生酸确定的炎症特征和内皮细胞炎症的变化
代谢产物和内皮细胞基因表达谱通过妇女绝经过渡期,
年龄匹配的男性有发生HFpEF的风险。本提案的总体目标是评估
假设全身炎症的性别差异可以解释观察到的HFpEF风险差异
以及男性和女性的疾病表现。这项研究将在一个
全面的职业发展计划,旨在为刘博士,一个早期的职业调查,
成为女性心血管(CV)健康方面的独立医生-科学家所需的技能。她的长-
长期职业目标是确定导致CV风险和疾病的生物性别差异,
女性CV疾病的预防和治疗策略。该提案汇集了一个独特的
由代谢组学、基因表达谱、妇女生殖健康和生殖健康等领域的专家组成的跨学科咨询小组
健康,和先进的生物统计学,将指导她的过渡到科学独立的候选人。
英文摘要
PROJECT SUMMARY/ABSTRACT
Heart failure (HF) is an important public health concern, affecting over 6 million individuals in the United States
alone. HF with preserved ejection fraction (HFpEF) is now the leading form of HF and the prevalence
continues to rise. HFpEF remains a therapeutic challenge, given our limited understanding of causal and
contributing factors, clinical heterogeneity within HFpEF subphenotypes, and lack of available therapies.
HFpEF is far more prevalent in women than men, driven in part by sex differences in cardiac structure and
remodeling, adaptations to physiologic stress, and comorbidity burden. Emerging data support the role of
systemic inflammation in the pathogenesis of HFpEF and sex differences in immune response have led many
to hypothesize that inflammation is an important driver of the female susceptibility to HFpEF. A better
understanding of these sex differences may offer critical insights into disease pathogenesis, particularly in light
of recent evidence highlighting potential therapeutic benefit of sacubitril/valsartan preferentially in women with
HFpEF. To date, investigations of inflammation in HFpEF have been limited to downstream markers of
inflammation. Eicosanoids are small bioactive lipids that regulate the upstream initiation of systemic
inflammation in humans. Advanced methods using mass spectrometry now allow for the rapid and accurate
quantification of >150 upstream eicosanoid mediators. We will leverage this state-of-the-art technology to
provide a more detailed understanding of how biologic sex differences in upstream eicosanoid pathways
contribute to HFpEF risk and disease progression. In Aim 1, we will examine sex differences in the association
of circulating eicosanoids with clinical antecedents of HFpEF as well as incident HFpEF in the community. In
Aim 2, we will evaluate the association of eicosanoid analytes with cardiac and extra-cardiac responses to
exercise in men and women with clinical HFpEF. In Aim 3, we will conduct a prospective observational study to
investigate the changes in inflammatory profiles and endothelial cell inflammation as ascertained by eicosanoid
metabolites and endothelial cell gene expression profiling through the menopausal transition in women and
age-matched men at risk for developing HFpEF. The overarching goal of this proposal is to evaluate the
hypothesis that sex differences in systemic inflammation may account for observed differences in HFpEF risk
and disease manifestations in men and women. This research will be accomplished in the setting of a
comprehensive career development program designed to provide Dr. Lau, an early career investigator, with the
skills needed to become an independent physician-scientist in women’s cardiovascular (CV) health. Her long-
term career goal is to identify biologic sex differences that contribute to CV risk and disease in order to refine
prevention and therapeutic strategies for women with CV disease. This proposal brings together a unique
interdisciplinary advisory team of experts in the fields of metabolomics, gene expression profiling, women’s
health, and advanced biostatistics that will guide the candidate in her transition to scientific independence.
期刊论文(12)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1177/17455057221140209
发表时间:
2022-01
期刊:
WOMENS HEALTH
影响因子:
2.4
作者:
[Kaur, Gurleen, Lau, Emily]
通讯作者:
Lau, Emily
Reply: Previous Pregnancies and Heart Failure Prognosis.
答复:既往妊娠史和心力衰竭预后。
DOI:
10.1016/j.jacc.2022.06.012
发表时间:
2022
期刊:
Journal of the American College of Cardiology
影响因子:
24
作者:
[Lau,EmilyS, Ho,JenniferE]
通讯作者:
Ho,JenniferE
A Women in Medicine Trainees' Council: a model for women trainee professional development.
女性医学实习生委员会:女性实习生职业发展的典范。
DOI:
10.1093/postmj/qgad018
发表时间:
2023
期刊:
Postgraduate medical journal
影响因子:
5.1
作者:
[Warner,ASofiaC, Ufere,NnekaN, Patel,NaomiJ, Lau,EmilyS, Uchida,AmikoM, Hills-Dunlap,Kelsey, Bromberg,GabrielleK, Cunningham,ElizabethA, Tagerman,MichelleD, Mills,GabrielleG, Palamara,Kerri, Rigotti,NancyA, Burnett-Bowie,Sherri-Ann]
通讯作者:
Burnett-Bowie,Sherri-Ann
DOI:
10.1161/circulationaha.122.061559
发表时间:
2023-02-14
期刊:
CIRCULATION
影响因子:
37.8
作者:
[Cho, Leslie, Kaunitz, Andrew M., Lindley, Kathryn J.]
通讯作者:
Lindley, Kathryn J.
Infertility and Subclinical Antecedents of Heart Failure With Preserved Ejection Fraction in the Framingham Heart Study.
弗雷明汉心脏研究中不孕症和保留射血分数的心力衰竭的亚临床前因。
DOI:
10.1016/j.cardfail.2023.10.482
发表时间:
2024
期刊:
Journal of cardiac failure
影响因子:
6
作者:
[Zhou,JoyceC, Zhao,Yunong, Bello,Natalie, Benjamin,EmeliaJ, Ramachandran,VasanS, Levy,Daniel, Cheng,Susan, Murabito,JoanneM, Ho,JenniferE, Lau,EmilyS]
通讯作者:
Lau,EmilyS
共 10 条
HFpEF Susceptibility in Women: The Role of Inflammation
-
批准号:10448571
-
项目类别:
-
资助金额:$19.97万
-
财政年份:2022
-
负责人:Emily Lau
-
依托单位:
海外基金